Muscle Relaxers for Pain Relief

Mechanism and Efficacy

The American Geriatrics Society notes that muscle relaxers do not directly relax tense skeletal muscles in humans, and their pain relief mechanism remains unclear, but may be related to sedative properties and inhibition of polysynaptic reflexes 1
For acute low back pain, skeletal muscle relaxants are moderately superior to placebo for short-term pain relief, with relative risk for not achieving pain relief of 0.80 at 2-4 days, according to the American College of Physicians 2, 3, 4
Adding a muscle relaxant to NSAIDs or acetaminophen provides greater short-term pain relief than analgesic monotherapy, though this increases CNS adverse events, as recommended by the American College of Physicians 5

Muscle relaxants are associated with 50% higher total adverse events and double the CNS adverse events compared to placebo, with common adverse effects including somnolence, dizziness, dry mouth, and increased fall risk, particularly concerning in older adults, according to the American Geriatrics Society 1, 2, 3, 6
Cyclobenzaprine is essentially identical to amitriptyline with similar anticholinergic side effects and potential toxicity in overdose, as noted by the American Geriatrics Society 1, 7

For acute musculoskeletal pain, the American College of Physicians recommends starting cyclobenzaprine 5 mg three times daily for 7-14 days maximum, combined with NSAIDs or acetaminophen for enhanced pain relief 5
The American Geriatrics Society advises avoiding muscle relaxants in older adults due to fall risk and anticholinergic effects 1
For suspected true muscle spasm, consider baclofen or benzodiazepines instead, which have actual effects on spasticity, as recommended by the American Geriatrics Society 1
Avoid muscle relaxants entirely for chronic pain conditions, as there is no evidence of benefit, according to the American College of Physicians 2, 8

The American Geriatrics Society recommends avoiding prolonged use of methocarbamol beyond 2 weeks due to increased risk of CNS adverse events, including somnolence, dizziness, and increased fall risk 9
Muscle relaxants, including methocarbamol, increase CNS adverse events by 2-fold compared to placebo, with a mechanism of pain relief that remains unclear and is not related to actual muscle relaxation 9

The American College of Physicians and the American Academy of Family Physicians recommend that topical NSAIDs (with or without menthol gel) be used as first‑line therapy for acute musculoskeletal pain, reserving oral NSAIDs or acetaminophen for second‑line treatment; methocarbamol should be added to these agents rather than used alone. Strength of recommendation: not specified. [10][11]12

The Centers for Disease Control and Prevention (CDC) MMWR advises clinicians never to prescribe methocarbamol “just in case” pain persists beyond the expected acute phase, emphasizing a time‑limited approach. Strength of recommendation: not specified. [13][14]15
The CDC MMWR further recommends that patients requiring methocarbamol beyond 7–10 days be re‑evaluated to confirm the diagnosis and consider alternative etiologies or therapies. Strength of recommendation: not specified. [13][14]15

CDC guidance for acute pain states that opioid prescriptions should rarely exceed 7 days; this principle is extended to muscle relaxants such as methocarbamol, supporting a maximum treatment duration of 2 weeks for acute musculoskeletal pain. Strength of recommendation: not specified. [13][14]15